RPL22L1 and colorectal carcinoma: Indeed, 5-FU based chemotherapy is a mainstay of CRC treatment [14, 28–30] and ectopic expression of RPL22L1 enhances 5-FU resistance, which is associated with both increased MGMT expression and decreased expression of the MMR gene, MLH1.